People: Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

2 Jul 2020
Change (% chg)

$-0.26 (-1.23%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Osborne, Aaron 

Dr. Aaron Osborne serves as Chief Medical Officer of the Company. Dr. Osborne has served as our chief medical officer since April 2019. Dr. Osborne has over twelve years of experience in the biopharmaceutical industry together with five years of clinical practice in the British National Health Service as an ophthalmologist. Prior to joining Adverum, Dr. Osborne was principal medical director since September 2018, and senior medical director from September 2015 through August 2018, of Ophthalmology Product Development at Genentech Inc., a biotechnology company, where he was responsible for leading clinical development programs for faricimab in wet age-related macular degeneration and diabetic macular edema, and academic collaborations. From August 2013 through May 2015, Dr. Osborne was the pharmaceuticals franchise head, Global Medical Affairs for Alcon Research Ltd., an eye care company, where he was responsible for developing global medical affairs plans for strategic marketed Alcon brands and for medical communications around Alcon retina programs. Prior to Alcon, Dr. Osborne served as global medical affairs head, Ophthalmics, at Novartis Pharma AG from December 2012 to August 2013, and as global brand medical director, Lucentis, at Novartis Pharma AG from December 2010 to August 2013. Dr. Osborne trained in ophthalmology at Queens Medical Center, Nottingham, and earned his Bachelor of Medicine, Bachelor of Surgery (MBBS) degree at University College London.

Basic Compensation

Total Annual Compensation, USD 543,750
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,838,450
Fiscal Year Total, USD 2,382,200

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --